Santen Pharmaceutical and Aerie Pharmaceuticals have entered into an exclusive development and commercialization agreement for Rhopressa and Rocklatan in Japan, according to a press release.
The agreement also includes rights in several other Asian countries.
Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution, Aerie) are already approved by the FDA. In Japan, the first phase 3 study for Rhopressa is in the preparation stage and will likely begin by the end of the year, the release said.
Aerie will receive an upfront
Uncategorized